Skip to main content
SpringerLink
Log in

Protocols

  • Chapter
  • First Online:
The Golden Guide to Oncologic Pharmacy

  • 637 Accesses

Abstract

The basic treatment for onco-hematologic diseases is chemotherapy. This methodology uses chemical compounds, called chemotherapeutics, in the treatment of diseases caused by biological agents. When applied to cancer, it is called anti-cancer chemotherapy.

The chapter proposes to highlight, elucidate, and understand the chemotherapy protocols used in different types of neoplasms, with updated doses and cycles.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Amaral LBMX. Cuidado de enfermagem nos efeitos adversos na quimioterapia para câncer de mama: revisão narrativa da literatura. Monografia (Graduação em Enfermagem) – Universidade Federal do Tocantins. Palmas; 2019. p. 50.

    Google Scholar 

  2. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria conjunta n° 5: aprova as diretrizes Diagnósticas e Terapêuticas do Carcinoma de Mama. Brasília-DF. 2019.

    Google Scholar 

  3. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2019.

    Google Scholar 

  4. Chisesi T. State of the art in the treatment of CLL. Rev Bras Hematol Hemoter. 2009;31(2):51–6.

    Google Scholar 

  5. Farias MG, Castro SM. Diagnóstico laboratorial das leucemiaslinfóides agudas. J Bras Patol Med Lab. 2004;40(2):91–8.

    Article  Google Scholar 

  6. Galvan ADC, Porath H. Perfil epidemiológico de pacientes que desenvolveram insuficiência cardíaca em tratamento com trastuzumabe para câncer de mama HER-2 positivo em centro de oncologia de hospital universitário. Monografia (Graduação em Medicina) – Faculdade Evangélica Mackenzie do Paraná. Curitiba; 2020. p. 58.

    Google Scholar 

  7. Howlader N, et al., editors. SEER cancer statistics review, 1975–2014. National Cancer Institute: Bethesda; 2017.

    Google Scholar 

  8. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Coordenação de Prevenção e Vigilância. Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2017.

    Google Scholar 

  9. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Coordenação de Prevenção e Vigilância. Estimativas 2016: incidência de câncer no Brasil [Internet]. Rio de Janeiro, INCA; 2015. Available from: http://www.inca.gov.br/estimativa/2016/estimativa-2016-v11.pdf.

  10. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). ABC do câncer: abordagens básicas para o controle do câncer [Internet]. Rio de Janeiro: INCA; 2017. Available from: http://www1.inca.gov.br/inca/Arquivos/comunicacao/livro_abc_3ed_8a_prova_final.pdf.

    Google Scholar 

  11. Kameo SY, Silva GM, Sawada NO, Santana ME. Neutropenia febril de recorrência pós-quimioterapia em paciente com câncer de mama. Rev Enferm UFPI. 2015;4(2):111–8.

    Article  Google Scholar 

  12. Lucarelli AP, Martins MM, Forattini A. Inibidores da aromatase no tratamento de pacientes com câncer de mama. Arq Med HospFacCienc Med Santa Casa São Paulo. 2013;58:88–91.

    Google Scholar 

  13. Lopes FC. Neutropenia febril no pacienteoncológico [Internet]. 2011.

    Google Scholar 

  14. Martinez AS, Queiroz FJG, Cangiani EE. Estudo das características terapêuticas dos antineoplásicos orais. Revista Eletrônica de Ciências da Saúde. Centro Universitário Planalto do Distrito Federal – UNIPLAN. Águas Claras/DF. 2019;1(1):20–24.

    Google Scholar 

  15. Mesa MJ, Restrepo DM, Ramírez-Pulgarín S, Martínez-Sánchez LM, Gázquez MA, Forero JP. Perfil clínico y microbiológico de niños Con neutropenia febril posterior a tratamientos antineoplásicos tratados en una institución hospitalaria de Medellín (Colombia), 2009-2010: estudio de serie de casos. Arch med. 2015;15(1):25–32.

    Google Scholar 

  16. Nascimento AS, Mello EVSL, Schneider LCL, Almeida FLA. Principais tratamentos utilizados no combate ao câncer de mama: uma revisão de literatura. Arquivos do MUDI. 2019;23(3):201–19.

    Article  Google Scholar 

  17. Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO. Neutropenia: ocorrência e manejo em mulheres com câncer de mama em quimioterapia. Rev latinoamenferm [Internet]. 2014.

    Google Scholar 

  18. Piranda DN, Freitas-Alves DR, Vianna-Jorge R. Farmacogenética e Implicações Terapêuticas no Câncer de Mama. Revista Brasileira de Cancerologia. 2013;59(3):449–52.

    Article  Google Scholar 

  19. Sidney KMM, Romeu GA, Pinheiro CG. Estudo de reações adversas ao paclitaxel em pacientes com câncer de mama em um hospital de referência. Rev Bras Farm Hosp Serv Saúde São Paulo. 2017;8(1):37–42.

    Google Scholar 

  20. Silva, Colet da F, Araðjo, da Silva L, Frizzo, Nunes M. Neoplasias Hematológicas No Idoso: Uma Revisão. Rev Sau Int, Rio Grande do Sul. 2016;8(15):1–13.

    Google Scholar 

  21. Vasconcelos RC. Avaliação dos marcadores celulares por citometria de fluxo em pacientes com leucemia mieloide aguda. Rev Bras Hematol Hemoter. 2010;32(3):275–6.

    Article  Google Scholar 

  22. Sander CA, Flaig MJ, Jaffe ES. Cutaneous manifestations of lymphoma: a clinical guide based on the WHO classification. World Health Organization. Clin Lymphoma. 2001;2(2):86–100.; ; discussion 101–2. https://doi.org/10.3816/clm.2001.n.014.

    Article  CAS  PubMed  Google Scholar 

  23. Judith AF. Scientific advances and the evolution of diagnosis, subclassification and treatment of lymphoma. Arch Med Res. 2020;51(8):749–64. https://doi.org/10.1016/j.arcmed.2020.05.022. Epub 2020 Jun 14

    Article  CAS  Google Scholar 

  24. Eich HT, Heimann M, Stutzer H, Kriz J, Reiser M, Muller RP. Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin’s lymphomas treated with radiation therapy. Strahlenther Onkol. 2009;185(5):288–95.

    Article  Google Scholar 

  25. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24(10):1590–6.

    Article  CAS  Google Scholar 

  26. Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, et al. Fludarabine as a risk fator for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoeetic cell transplantation. Bone Marrow Transplant. 2012;47(4):488–93.

    Article  CAS  Google Scholar 

  27. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2017;10(3):239–49. https://doi.org/10.1080/17474086.2017.1281122. Epub 2017 Jan 29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–34.

    Article  CAS  Google Scholar 

  29. Swerdlow SHA. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  30. Rajkumar SV. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538–48.

    Article  Google Scholar 

  31. Pasqualini C, Rialland F, Valteau-Couanet D, Michon J, Minard-Colin V. Nouvelles perspectives dans l'immunothérapie des cancer pédiatriques. Bull Cancer. 2018;105(Suplemento 1):S68–79. https://doi.org/10.1016/S0007-4551(18)30392-8.

    Article  PubMed  Google Scholar 

  32. Snaman J, Kaye EC, Baker JN, Wolfe J. Pediatric palliative oncology: the state of the science and art of caring for children with cancer. Curr Opin Pediatr. 2018;30(1):40–8. https://doi.org/10.1097/MOP.0000000000000573.

    Article  PubMed  Google Scholar 

  33. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de AtençãoEspecializada e Temáticas. Protocolo de diagnóstico precoce do câncer pediátrico [recursoeletrônico]/Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de AtençãoEspecializada e Temáticas. Brasília: Ministério da Saúde; 2017.

    Google Scholar 

  34. Weirich A, Leuschner I, Harms D, Vujanic GM, Troger J, Abel U, et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol. 2001;12:311–9.

    Article  CAS  Google Scholar 

  35. Charlton J, Irtan S, Bergeron C, Pritchard-Jones K. Bilateral Wilms tumour: a review of clinical and molecular features. Expert Rev Mol Med. 2017;18(19):e8. https://doi.org/10.1017/erm.2017.8.

    Article  CAS  Google Scholar 

  36. Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240–51. https://doi.org/10.1038/s41581-019-0112-0.

    Article  PubMed  Google Scholar 

  37. Filbin M, Monje M. Developmental origins and emerging therapeutic opportunities for childhood. Cancer Nat Med. 2019 Mar;25(3):367–76. https://doi.org/10.1038/s41591-019-0383-9.

    Article  CAS  PubMed  Google Scholar 

  38. Landier W, Armenian S, Bhatia S. Late effects of childhood cancer and its treatment. Pediatr Clin N Am. 2015 Feb;62(1):275–300. https://doi.org/10.1016/j.pcl.2014.09.017.

    Article  Google Scholar 

  39. Williams MTS, Yousafzai YM, Elder A, Rehe K, Bomken S, LironFrishman-Levy ST, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JAE, Izraeli S, Vormoor J, Graham GJ, Halsey C. The ability to cross the blood–cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts Crossmark: check for updates. Blood. 2016;127(16):1998–2006.

    Article  CAS  Google Scholar 

  40. Levinsen M, Marquart HV, Groth-Pedersen L, Abrahamsson J, Albertsen BK, Andersen MK, Frandsen TL, Harila-Saari A, Pronk C, Ulvmoen A, Vaitkevičienė G, Lähteenmäki PM, Niinimäki R, MerviTaskinen MJ, Schmiegelow K. Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases. Pediatr Blood Cancer. 2016;63(11):1935–42. https://doi.org/10.1002/pbc.26128. Epub 2016 Jul 22.

    Article  CAS  PubMed  Google Scholar 

  41. Vora A, Andreano A, Pui C-H, Hunger SP, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman LB, Goulden N, Taskinen M, Pieters R, KeizoHoribe MD, Locatelli F, Valsecchi MG. Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016;34(9):12–17.

    Google Scholar 

  42. Messina M, Del Giudice I, Khiabanian H, Rossi D, Chiaretti S, Rasi S, Spina V, Holmes AB, Marinelli M, Fabbri G, Piciocchi A, Mauro FR, Guarini A, Gaidano G, Dalla-Favera R, Pasqualucci L, Rabadan R, Foà R. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Crossmark: Check for Updates. Blood. 2014;123(15):2378–88.

    Article  CAS  Google Scholar 

  43. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, M Baccarani on behalf of the GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823–31. © 2015 Macmillan Publishers Limited

    Article  CAS  Google Scholar 

  44. Vij R, Kumar S, Zhang M-J, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, BaldeepWirk PN, editors. Hari impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21:335e341.

    Google Scholar 

  45. Ning C, Zhao T, Wang Z, Li D, Kou Y, Huang S. Cervical lymph node metastases in salivary gland adenoid cystic carcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:10–14.

    Google Scholar 

  46. Sun X, ShengfaSu CC, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403. https://doi.org/10.1016/j.radonc.2013.10.020. Epub 2013 Nov 11

    Article  PubMed  Google Scholar 

  47. Tang L-Q, Lu T-Y, Yang L, Guo S-Y, Zhong Q-Y, Zou M-S, Chen B-L, Tang Q-N, Chen W-H, Guo S-S, Liu L-T, Chen Q-Y, Guo L, Mo H-Y, Dong RS. Patterns of failure and survival trends of 720 patients with stage I nasopharyngeal carcinoma diagnosed from 1990-2012: a large-scale retrospective cohort study. J Cancer. 2018;9:7–13.

    Google Scholar 

  48. ESCÓRCIO et al. Study pharmacokinect and pharmacodynamic profile of the substances used in breast cancer treatment. Revista Saúde em Foco, Teresina. v. 4, n. 1, art. 6, p. 67–93, jan./jul.2017.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jesus Maria José Maternity Hospital, Quixadá, Ceará, Brazil

    Kaléu Mormino Otoni

  2. Postgraduate Program in Integrated and Multidisciplinary Care for Women’s and Children’s Health, Federal University of Ceará, University Campus – Rectory, PICI, Fortaleza, CE, Brazil

    Kaléu Mormino Otoni

  3. Catholic University Center of Quixadá, Unicatólica, Quixadá, Ceará, Brazil

    Karla Bruna Nogueira Torres Mormino

  4. Graduate Program in Pharmaceutical Sciences, Federal University of Ceará, Fortaleza, CE, Brazil

    Sandna Larissa Freitas dos Santos & Maria Liliane Luciano Pereira

Authors
  1. Kaléu Mormino Otoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karla Bruna Nogueira Torres Mormino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandna Larissa Freitas dos Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Liliane Luciano Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pediatric Oncology Pharmacist & Writer, Curitiba, Paraná, Brazil

    Carolina Witchmichen Penteado Schmidt

  2. Jesus Maria José Maternity Hospital, Quixadá, Ceará, Brazil

    Kaléu Mormino Otoni

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Otoni, K.M., Mormino, K.B.N.T., dos Santos, S.L.F., Pereira, M.L.L. (2022). Protocols. In: Schmidt, C.W.P., Otoni, K.M. (eds) The Golden Guide to Oncologic Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-98596-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98596-7_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-98595-0

  • Online ISBN: 978-3-030-98596-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation